Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amoxylet CV is an oral combination antibiotic developed by Saanso Pharma, containing amoxicillin (500mg) and clavulanic acid (125mg). Amoxicillin is a semi-synthetic aminopenicillin that inhibits bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBPs), which are essential for the cross-linking of peptidoglycan chains. This leads to bacterial cell lysis and death. Clavulanic acid is a beta-lactamase inhibitor that structurally resembles beta-lactam antibiotics; it covalently binds to and inhibits beta-lactamase enzymes produced by resistant bacteria, thereby preventing the degradation of amoxicillin and extending its spectrum of activity. The combination is used to treat various bacterial infections including those of the respiratory tract, urinary tract, skin, and soft tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Amoxylet CV.